Long-Term Safety and Efficacy of Bimatoprost Solution 0.03% Application to the Eyelid Margin for the Treatment of Idiopathic and Chemotherapy-Induced Eyelash Hypotrichosis: A Randomized Controlled Trial

In a multicenter, double-masked, randomized, parallel-group study, the long-term safety and efficacy of bimatoprost ophthalmic solution 0.03% were evaluated over two 6-month treatment periods for patients with idiopathic or chemotherapy-induced eyelash hypotrichosis. The study met its primary efficacy endpoint at month 4, with a 40.2% responder rate for idiopathic hypotrichosis patients using bimatoprost compared to 6.8% for the vehicle, and a 37.5% responder rate for post-chemotherapy patients using bimatoprost versus 18.2% for the vehicle. By month 6, the efficacy was maintained or enhanced, and effects lasted approximately 2 months after treatment cessation but significantly decreased after 4-6 months in idiopathic hypotrichosis patients. No serious drug-related adverse events were reported, indicating that daily treatment with bimatoprost ophthalmic solution 0.03% for 1 year is effective and well-tolerated for these conditions.